Supplementary Fig. S4 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Yoshinaga Ito,Deng Pan,Wubing Zhang,Xixi Zhang,Tiffany Y. Juan,Jason W. Pyrdol,Oleksandr Kyrysyuk,John G. Doench,X. Shirley Liu,Kai W. Wucherpfennig

DOI: https://doi.org/10.1158/2159-8290.22674276

2023-01-01

Abstract:Supplementary Fig. S4 shows differentially expressed genes revealed by RNA-seq analysis.

What problem does this paper attempt to address?

Table S3 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Yoshinaga Ito,Deng Pan,Wubing Zhang,Xixi Zhang,Tiffany Y. Juan,Jason W. Pyrdol,Oleksandr Kyrysyuk,John G. Doench,X. Shirley Liu,Kai W. Wucherpfennig

DOI: https://doi.org/10.1158/2159-8290.22674252

2023-01-01

Abstract:Supplementary Table S3: ## Raw count matrix of the RNA-seq data. ## Atg5-KO vs Ctrl-KO (Veh).
Supplementary Fig. S7 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Yoshinaga Ito,Deng Pan,Wubing Zhang,Xixi Zhang,Tiffany Y. Juan,Jason W. Pyrdol,Oleksandr Kyrysyuk,John G. Doench,X. Shirley Liu,Kai W. Wucherpfennig

DOI: https://doi.org/10.1158/2159-8290.22758764.v1

2023-01-01

Abstract:Supplementary Fig. S7 shows effect of PD-1 inhibition on treatment of tumors containing a B2m-/- population.
Supplementary Fig. S5 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Yoshinaga Ito,Deng Pan,Wubing Zhang,Xixi Zhang,Tiffany Y. Juan,Jason W. Pyrdol,Oleksandr Kyrysyuk,John G. Doench,X. Shirley Liu,Kai W. Wucherpfennig

DOI: https://doi.org/10.1158/2159-8290.22674273

2023-01-01

Abstract:Supplementary Fig. S5 shows association of Atg5-KO and Rnf31/Atg5-dKO signatures with patient survival.
Supplementary Fig. S8 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines

Yoshinaga Ito,Deng Pan,Wubing Zhang,Xixi Zhang,Tiffany Y. Juan,Jason W. Pyrdol,Oleksandr Kyrysyuk,John G. Doench,X. Shirley Liu,Kai W. Wucherpfennig

DOI: https://doi.org/10.1158/2159-8290.22758761.v1

2023-01-01

Abstract:Supplementary Fig. S8 shows CD8 T cell-dependent control of tumors containing a B2m-/- population with inactivated Rnf31 and Atg5 genes.
Supplementary Fig. S9 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Yoshinaga Ito,Deng Pan,Wubing Zhang,Xixi Zhang,Tiffany Y. Juan,Jason W. Pyrdol,Oleksandr Kyrysyuk,John G. Doench,X. Shirley Liu,Kai W. Wucherpfennig

DOI: https://doi.org/10.1158/2159-8290.22674261

2023-01-01

Abstract:Supplementary Fig. S9 shows enhanced IFNg and TNFa expression by T cells and NK cells in Rnf31/Atg5-dKO tumors.
Figure S4 from Dissecting LncRNA Roles in Renal Cell Carcinoma Metastasis and Characterizing Genomic Heterogeneity by Single-Cell RNA-seq

Xue Li,Xiuxia Meng,Cong Wang,Yincong Zhou,Hongjun Chen,Haibo He,Ming Chen

DOI: https://doi.org/10.1158/1541-7786.22510831

2023-01-01

Abstract:Figure S4. 173 differentially expressed lncRNAs profiling of all single cells.
P02.05 Comprehensive Profiling of Tumor Heterogeneity and Its Microenvironment in Advanced Non-Small Cell Lung Cancer at Single Cell Resolution

Y. Cordts,F. Wu,J. Fan,M. Odenthal,R. Buettner,C. Zhou

DOI: https://doi.org/10.1136/jitc-2021-itoc8.17

2021-01-01

Abstract:Background Lung cancer is a highly heterogeneous disease. Cancer cells and cells within the tumor microenvironment together determine disease progression, as well as response to or escape from treatment. Materials and Methods To map the cell type-specific transcriptome landscape of cancer cells and their tumor microenvironment in advanced non-small cell lung cancer (NSCLC), we analyzed 42 tissue biopsy samples from stage III/IV NSCLC patients by single cell RNA sequencing and presented the large scale, single cell resolution profiles of advanced NSCLCs. Results In addition to cell types described in previous single cell studies of early stage lung cancer, we were able to identify new cell types such as follicular dendritic cells and T helper 17 cells. Tumors from different patients display large heterogeneity in cellular composition, chromosomal structure, developmental trajectory, intercellular signaling network and phenotype dominance. Our study also revealed a correlation of tumor heterogeneity with tumor associated neutrophils, which might help to shed light on their function in NSCLC. Conclusions This study presented first-time the tumor heterogeneity and tumor microenvironment profile from late-stage, largely untreated NSCLC patients, and shed light on possible treatment regimes. Disclosure Information Y. Cordts: A. Employment (full or part-time); Modest; Singleron Biotechnologies GmbH. F. Wu: None. J. Fan: A. Employment (full or part-time); Modest; Singleron Biotechnologies GmbH. M. Odenthal: None. R. Buettner: None. C. Zhou: None.
Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell-Secreted Cytokines.

Yoshinaga Ito,Deng Pan,Wubing Zhang,Xixi Zhang,Tiffany Y. Juan,Jason W. Pyrdol,Oleksandr Kyrysyuk,John G. Doench,X. Shirley Liu,Kai W. Wucherpfennig

DOI: https://doi.org/10.1158/2159-8290.cd-22-1125

2023-01-01

Abstract:Abstract Tumor heterogeneity is a major barrier to cancer therapy, including immunotherapy. Activated T cells can efficiently kill tumor cells following recognition of MHC class I (MHC-I)–bound peptides, but this selection pressure favors outgrowth of MHC-I–deficient tumor cells. We performed a genome-scale screen to discover alternative pathways for T cell–mediated killing of MHC-I–deficient tumor cells. Autophagy and TNF signaling emerged as top pathways, and inactivation of Rnf31 (TNF signaling) and Atg5 (autophagy) sensitized MHC-I–deficient tumor cells to apoptosis by T cell–derived cytokines. Mechanistic studies demonstrated that inhibition of autophagy amplified proapoptotic effects of cytokines in tumor cells. Antigens from apoptotic MHC-I–deficient tumor cells were efficiently cross-presented by dendritic cells, resulting in heightened tumor infiltration by IFNγ-and TNFα-producing T cells. Tumors with a substantial population of MHC-I–deficient cancer cells could be controlled by T cells when both pathways were targeted using genetic or pharmacologic approaches. Significance: Tumor heterogeneity is a major barrier to immunotherapy. We show that MHC-I–deficient tumor cells are forced into apoptosis by T cell–derived cytokines when TNF signaling and autophagy pathways are targeted. This approach enables T cell–mediated elimination of tumors with a substantial population of resistant, MHC-I–deficient tumor cells. This article is highlighted in the In This Issue feature, p. 1027
Supplementary Figure S9 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Jason Bugno,Liangliang Wang,Xianbin Yu,Xuezhi Cao,Jiaai Wang,Xiaona Huang,Kaiting Yang,Andras Piffko,Katherine Chen,Stephen Y. Luo,Emile Naccasha,Yuzhu Hou,Sherry Fu,Chuan He,Yang-xin Fu,Hua L. Liang,Ralph R. Weichselbaum

DOI: https://doi.org/10.1158/1078-0432.27142111

2024-01-01

Abstract:Supplementary Figure S9. Changes in gene expression associated with ISG + cDC2 among sequencing results
Supplementary Figure from Comprehensive Characterizations of Immune Receptor Repertoire in Tumors and Cancer Immunotherapy Studies

Li Song,Zhangyi Ouyang,David Cohen,Yang Cao,Jennifer Altreuter,Gali Bai,Xihao Hu,Kenneth J. Livak,Heng Li,Ming Tang,Bo Li,X. Shirley Liu

DOI: https://doi.org/10.1158/2326-6066.22544670.v1

2023-01-01

Abstract:Supplementary Figure from Comprehensive Characterizations of Immune Receptor Repertoire in Tumors and Cancer Immunotherapy Studies
Supplementary file from Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy

Xue-Bin Ran,Ling-Wen Ding,Qiao-Yang Sun,Henry Yang,Jonathan W. Said,Lao Zhentang,Vikas Madan,Pushkar Dakle,Jin-Fen Xiao,Xinyi Loh,Ying Li,Liang Xu,Xiao-Qiang Xiang,Ling-Zhi Wang,Boon Cher Goh,De-Chen Lin,Wee Joo Chng,Soo-Yong Tan,Sudhakar Jha,H. Phillip Koeffler

DOI: https://doi.org/10.1158/0008-5472.22432644.v1

2023-01-01

Abstract:This file contains supplementary methods, Figs. S1 to S6 and Tables S1 to S5.
Supplementary Table S1 from Integrative Single-Cell and Bulk Transcriptomes Analyses Identify Intrinsic HNSCC Subtypes with Distinct Prognoses and Therapeutic Vulnerabilities

Yibin Dai,Ziyu Wang,Yi Xia,Li Jin,Yaping Wu,Yanling Wang,Hongbing Jiang,Jie Cheng

DOI: https://doi.org/10.1158/1078-0432.23814224

2023-01-01

Abstract:Detailed proportions of cells in 5 scRNA-seq datasets
Unravelling the Heterogeneity and Dynamic Relationships of Tumor-Infiltrating T Cells by Single-Cell RNA Sequencing Analysis

Xin Yu,Lei Zhang,Ashutosh Chaudhry,Aaron S. Rapaport,Wenjun Ouyang

DOI: https://doi.org/10.1002/jlb.6mr0320-234r

2020-01-01

Journal of Leukocyte Biology

Abstract:T cells are crucial for the success of immune-based cancer therapy. Reinvigorating antitumor T cell activity by blocking checkpoint inhibitory receptors has provided clinical benefits for many cancer patients. However, the efficacy of these treatments varies in cancer patients and the mechanisms underlying these diverse responses remain elusive. The density and status of tumor-infiltrating T cells have been shown to positively correlate with patient response to checkpoint blockades. Therefore, further understanding of the heterogeneity, clonal expansion, migration, and effector functions of tumor-infiltrating T cells will provide fundamental insights into antitumor immune responses. To this end, recent advances in single-cell RNA sequencing technology have enabled profound and extensive characterization of intratumoral immune cells and have improved our understanding of their dynamic relationships. Here, we summarize recent progress in single-cell RNA sequencing technology and current strategies to uncover heterogeneous tumor-infiltrating T cell subsets. In particular, we discuss how the coupling of deep transcriptome information with T cell receptor (TCR)-based lineage tracing has furthered our understanding of intratumoral T cell populations. We also discuss the functional implications of various T cell subsets in tumors and highlight the identification of novel T cell markers with therapeutic or prognostic potential.
Table S1 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Yoshinaga Ito,Deng Pan,Wubing Zhang,Xixi Zhang,Tiffany Y. Juan,Jason W. Pyrdol,Oleksandr Kyrysyuk,John G. Doench,X. Shirley Liu,Kai W. Wucherpfennig

DOI: https://doi.org/10.1158/2159-8290.22758755.v1

2023-01-01

Abstract:Supplementary Table S1: # Raw count of the genome-wide CRISPR screen for identifying T cell-mediated tumor killing in B2m-deficient cells. # MAGeCK results (Gene summary) for the genome-wide CRISPR screen from the B2m-deficient cells. # Gene log2FC in CRISPR screens from B2m-WT cells and B2m-KO cells. ## Common regulators of T cell mediated tumor killing in both B2m-WT and B2m-KO cells
Supplementary Figure S4 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Jason Bugno,Liangliang Wang,Xianbin Yu,Xuezhi Cao,Jiaai Wang,Xiaona Huang,Kaiting Yang,Andras Piffko,Katherine Chen,Stephen Y. Luo,Emile Naccasha,Yuzhu Hou,Sherry Fu,Chuan He,Yang-xin Fu,Hua L. Liang,Ralph R. Weichselbaum

DOI: https://doi.org/10.1158/1078-0432.27142132

2024-01-01

Abstract:Supplementary Figure S4. Human expression of FOXP3 with RT and correlation with a Human DC_Ccl22 Homolog Score among TCGA cohorts
Supplementary Figure S8 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Jason Bugno,Liangliang Wang,Xianbin Yu,Xuezhi Cao,Jiaai Wang,Xiaona Huang,Kaiting Yang,Andras Piffko,Katherine Chen,Stephen Y. Luo,Emile Naccasha,Yuzhu Hou,Sherry Fu,Chuan He,Yang-xin Fu,Hua L. Liang,Ralph R. Weichselbaum

DOI: https://doi.org/10.1158/1078-0432.27142117

2024-01-01

Abstract:Supplementary Figure S8. Bulk RNA-sequencing of tumor myeloid cells 7 days after RT and αEGFR-IFNα
Supplementary Figure S1 from Intratumoral Heterogeneity in a Trp53-Null Mouse Model of Human Breast Cancer

Mei Zhang,Anna Tsimelzon,Chi-Hsuan Chang,Cheng Fan,Andrew Wolff,Charles M. Perou,Susan G. Hilsenbeck,Jeffrey M. Rosen

DOI: https://doi.org/10.1158/2159-8290.22529763

2023-01-01

Abstract:Supplementary Figure S1. Genetic characterization of the four individual subpopulations (PCR and CGH analysis).
Supplementary Figure 1 from Functional Genetic Variations in Cytotoxic T-Lymphocyte Antigen 4 and Susceptibility to Multiple Types of Cancer

Tong Sun,Yifeng Zhou,Ming Yang,Zhibin Hu,Wen Tan,Xiaohong Han,Yuankai Shi,Jiarui Yao,Yongli Guo,Dianke Yu,Tian Tian,Xiaoyi Zhou,Hongbing Shen,Dongxin Lin

DOI: https://doi.org/10.1158/0008-5472.22376705

2023-01-01

Abstract:Supplementary Figure 1 from Functional Genetic Variations in Cytotoxic T-Lymphocyte Antigen 4 and Susceptibility to Multiple Types of Cancer
Supplementary Tables from in Vivo Visualization and Characterization of Epithelial–Mesenchymal Transition in Breast Tumors

Zhen Zhao,Xiaoping Zhu,Kemi Cui,James Mancuso,Richard Federley,Kari Fischer,Gao-jun Teng,Vivek Mittal,Dingcheng Gao,Hong Zhao,Stephen T.C. Wong

DOI: https://doi.org/10.1158/0008-5472.22412100.v1

2023-01-01

Abstract:Table 1: Distribution of the GFP+ cells in whole tumor central vs peripheral area and tumor lobule central vs peripheral area. Table 2: RNAseq gene expressions of growth factor receptors in sorted RFP+ and GFP+ cells.
Supplementary Tables 1 - 4 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Feng Xu,Jing Liu,Di Liu,Biao Liu,Min Wang,Zhiyuan Hu,Xuemei Du,Li Tang,Fuchu He

DOI: https://doi.org/10.1158/0008-5472.22399923.v1

2023-01-01

Abstract:PDF file - 71KB, Supplementary Table 1 Characteristics of 7 types of cancer patient in cancer survey array. Supplementary Table 2 Characteristics of patient in melanoma RNA chip. Supplementary Table 3 Characteristics of patient in melanoma IHC chip. Supplementary Table 4. Characteristics of patient in flow cytometry analysis.

Supplementary Fig. S4 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Table S3 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Supplementary Fig. S7 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Supplementary Fig. S5 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Supplementary Fig. S8 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines

Supplementary Fig. S9 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Figure S4 from Dissecting LncRNA Roles in Renal Cell Carcinoma Metastasis and Characterizing Genomic Heterogeneity by Single-Cell RNA-seq

P02.05 Comprehensive Profiling of Tumor Heterogeneity and Its Microenvironment in Advanced Non-Small Cell Lung Cancer at Single Cell Resolution

Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell-Secreted Cytokines.

Supplementary Figure S9 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Supplementary Figure from Comprehensive Characterizations of Immune Receptor Repertoire in Tumors and Cancer Immunotherapy Studies

Supplementary file from Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy

Supplementary Table S1 from Integrative Single-Cell and Bulk Transcriptomes Analyses Identify Intrinsic HNSCC Subtypes with Distinct Prognoses and Therapeutic Vulnerabilities

Unravelling the Heterogeneity and Dynamic Relationships of Tumor-Infiltrating T Cells by Single-Cell RNA Sequencing Analysis

Table S1 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Supplementary Figure S4 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Supplementary Figure S8 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Supplementary Figure S1 from Intratumoral Heterogeneity in a <i>Trp53</i>-Null Mouse Model of Human Breast Cancer

Supplementary Figure 1 from Functional Genetic Variations in <i>Cytotoxic T-Lymphocyte Antigen 4</i> and Susceptibility to Multiple Types of Cancer

Supplementary Tables from in Vivo Visualization and Characterization of Epithelial–Mesenchymal Transition in Breast Tumors

Supplementary Tables 1 - 4 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Supplementary Fig. S4 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Table S3 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Supplementary Fig. S7 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Supplementary Fig. S5 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Supplementary Fig. S8 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines

Supplementary Fig. S9 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Figure S4 from Dissecting LncRNA Roles in Renal Cell Carcinoma Metastasis and Characterizing Genomic Heterogeneity by Single-Cell RNA-seq

P02.05 Comprehensive Profiling of Tumor Heterogeneity and Its Microenvironment in Advanced Non-Small Cell Lung Cancer at Single Cell Resolution

Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell-Secreted Cytokines.

Supplementary Figure S9 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Supplementary Figure from Comprehensive Characterizations of Immune Receptor Repertoire in Tumors and Cancer Immunotherapy Studies

Supplementary file from Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy

Supplementary Table S1 from Integrative Single-Cell and Bulk Transcriptomes Analyses Identify Intrinsic HNSCC Subtypes with Distinct Prognoses and Therapeutic Vulnerabilities

Unravelling the Heterogeneity and Dynamic Relationships of Tumor-Infiltrating T Cells by Single-Cell RNA Sequencing Analysis

Table S1 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Supplementary Figure S4 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Supplementary Figure S8 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Supplementary Figure S1 from Intratumoral Heterogeneity in a &lt;i&gt;Trp53&lt;/i&gt;-Null Mouse Model of Human Breast Cancer

Supplementary Figure 1 from Functional Genetic Variations in &lt;i&gt;Cytotoxic T-Lymphocyte Antigen 4&lt;/i&gt; and Susceptibility to Multiple Types of Cancer

Supplementary Tables from in Vivo Visualization and Characterization of Epithelial–Mesenchymal Transition in Breast Tumors

Supplementary Tables 1 - 4 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Supplementary Figure S1 from Intratumoral Heterogeneity in a <i>Trp53</i>-Null Mouse Model of Human Breast Cancer

Supplementary Figure 1 from Functional Genetic Variations in <i>Cytotoxic T-Lymphocyte Antigen 4</i> and Susceptibility to Multiple Types of Cancer